The parallel elevation of tear VEGF in both the murine model and human AMD underscores the translational promise of tear-based assays, which could facilitate routine, non-invasive monitoring of disease activity and treatment efficacy in clinical practice [70]. This evidence concerns the gene VEGFA and age-related macular degeneration.